Improving research standards to restore trust in intranasal oxytocin

Biological Psychiatry

Volumn 79, Issue 8, 2016, Pages e53-e54

  Carson, Dean S ^a   Yuan, Hsiangkuo ^b   Labuschagne, Izelle ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OXYTOCIN;

BLOOD BRAIN BARRIER; BRAIN TISSUE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG BRAIN LEVEL; DRUG EFFECT; FUNCTIONAL NEUROIMAGING; HUMAN; ISOTOPE LABELING; LETTER; MEDICAL LITERATURE; NONHUMAN; OLFACTORY SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RESEARCH ETHICS; TRIGEMINAL NERVE; TRUST; WORLD HEALTH ORGANIZATION; INTRANASAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; OXYTOCIN; TRUST;

EID: 84961207031     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.08.031     Document Type: Letter

References (15)

1. G. Leng, and M. Ludwig Intranasal oxytocin: myths and delusions Biol Psychiatry. 2015
2. International Conference on Harmonisation: Good clinical practice. Consolidated guideline 1996. Available at: http://www.ich.org/.
3. World Health Organization (1995): Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. Annex 3 of The Use of Essential Drugs Sixth Report of the WHO Expert Committee. Geneva: Available at: http://www.who.int/medicines/en/.
4. D. Rennie CONSORT revised - improving the reporting of randomized trials JAMA 273 2001 408 412
5. The International Committee of Medical Journal Editors (2013): Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. Available at: http://www.icmje.org.
6. L.P. Freedman, I.M. Cockburn, and T.S. Simcoe The economics of reproducibility in preclinical research PloS Biol 13 2015 e1002165
7. J.P. Garner The significance of meaning: Why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it? Ilar J 55 2014 438 456
8. National Institutes of Health (2014): Proposed principles and guidelines for reporting preclinical research. Available at: http://www.nih.gov/about/reporting-preclinical-research.htm.
9. F. Calcagnoli, J.C. Kreutzmann, S.F. de Boer, M. Althaus, and J.M. Koolhaas Acute and repeated intranasal oxytocin administration exerts anti-aggressive and pro-affiliative effects in male rats Psychoneuroendocrinology 51 2015 112 121
10. T. Watanabe, O. Abe, H. Kuwabara, N. Yahata, Y. Takano, N. Iwashiro, and et al. Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: A randomized trial JAMA Psychiatry 71 2014 166 175
11. C.S. Sripada, K.L. Phan, I. Labuschagne, R. Welsh, P.J. Nathan, and A.G. Wood Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex Int J Neuropsychopharmacol 16 2013 255 260
12. S. Dodhia, A. Hosanagar, D.A. Fitzgerald, I. Labuschagne, A.G. Wood, P.J. Nathan, and et al. Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder Neuropsychopharmacology 39 2014 2061 2069
13. J.J. Lochhead, and R.G. Thorne Intranasal delivery of biologics to the central nervous system Adv Drug Deliv Rev 64 2012 614 628
14. R.G. Thorne, G.J. Pronk, V. Padmanabhan, and W.H. Frey Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration Neuroscience 127 2004 481 496
15. S.V. Dhuria, L.R. Hanson, and W.H. Frey II Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system J Pharmacol Exp Ther 328 2009 312 320